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Epstein-Barr Virus is associated with several neoplasms in man. It is presumed to be 
the causative agent of infectious mononucleosis (1), a  self-limiting lymphoproliferative 
disease,  and is consistently associated with nasopharyngeal carcinoma (NPC)  (2) ~ and 
African Burkitt's lymphoma (BL) (3). Viral isolates from the throat washings of patients 
with infectious mononucleosis can transform normal human lymphocytes in vitro giving 
rise to lymphoblastoid cell lines which express the Epstein-Barr (EB)  nuclear antigen, 
carry multiple copies  of the viral genome, and are of B-cell  origin (4-6).  Transforming 
Epstein-Barr virus (EBV)  may also be used to induce lymphomas in marmosets from 
which virus-producing lymphoblastoid cell  lines may be established  (7). One such line, 
B95-8, has been used extensively as a source of transforming EBV (8). 
Little is known about the mechanism by which EBV infects B lymphocytes, how the 
lymphoproliferation typical of infectious mononucleosis is controlled, and the nature of 
the breakdown in these controls during NPC and BL.  A role of humoral immunity is 
protection against reinfection is suggested by the persistance of anti-EBV neutralizing 
titers after EBV infection (9). The possibility of cellular immunity during the acute phase 
of infectious mononucleosis (IM)  has been suggested by the presence of cytotoxic cells 
specific  for  EBV-carrying cell  lines  (10); however,  the  levels  of killing  reported  are 
variable.  After recovery from IM the viral infection is not completely eliminated but is 
carried in some latent or suppressed form, as healthy seropositive individuals appear to 
carry infected cells at a very low number.  These cells must exist because outgrowth of 
EBV-positive lymphoblastoid cell lines may be achieved from the lymphocytes of seropo- 
sitive individuals without the addition of exogenous virus. In vitro culture of fetal cord 
lymphocytes or lymphocytes from seronegative donors does not result in such an out- 
growth (11). 
The  studies  presented  here  were  prompted  by  the  observation  that  adult 
lymphocytes transform  and  immortalize  in  vitro  much  less  efficiently  than 
lymphocytes from fetal cord blood (12).  They indicate that there is little differ- 
ence in the susceptibility of adult or fetal B lymphocytes to infection. However, 
the adult Ig-negative  2 population has a strongly inhibitory effect when added to 
the infection mixture. This inhibition is not exhibited by the same fetal lympho- 
* Supported by grants AI-09576 and RR05526 from the National Institutes of Health. 
~Abbreviations  used  in  this  paper:  B cell, surface  Ig-positive lymphocytes; BL,  Burkitt's 
lymphoma; cpm, counts per minute; EBV, Epstein-Barr virus; IM, infectious mononucleosis; NPC, 
nasopharyngeal  carcinoma; PBL, peripheral  blood lymphocyte. 
Ig-negative cell, all non-B-type lymphocytes. This population is > 90% T cell. However, it also 
contains a small population of Null lymphocytes which are distinct from T cells both in surface 
markers  and in function. For accuracy this population will be termed Ig negative. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  •  VOLUME  146,  1977  495 496  SUPPRESSION  OF  IN  VITRO  EPSTEIN-BARR  VIRUS  INFECTION 
cyte  population.  It  is  proposed that  this  in  vitro  effect is  the  result  of the 
development in vivo of a mechanism during maturation for controlling the viral 
infection and maintaining  it in a suppressed form. 
Materials  and  Methods 
Virus.  Transforming virus was obtained from the supernate of the B95-8 marmoset lympho- 
blastoid line.  The cell line  (originally obtained from The John L.  Smith Memorial for Cancer 
Research Inc., Maywood, N. J.) was carried in medium RPMI 1640 (Grand Island Biological Co., 
Grand Island, N. Y.) containing, 10% fetal calf serum, 100 tLg/ml streptomycin, 100 U/ml penicillin, 
and 300 t~g/ml glutamine. The cells were fed by diluting to 0.5 × 10  ~  cells/ml every 3-4 days and were 
kept in a 5% CO2 humidified atmosphere at 37°C. To obtain maximal production of virus the cells 
were kept for 12 days from the last feeding at 37°C before harvesting. After this time the cells were 
removed by centrifuging at 2-3,000  g  in the Sorvall RC-3.  (Ivan Sorvall,  Inc., Norwalk,  Conn.) 
The clear supernate may be filtered through a  0.45-t~m  filter at this stage without loss of viral 
activity as judged by induction of DNA synthesis in B lymphocytes. The supernate was then stored 
in aliquots at  -80°C. Viral activity was very sensitive to freezing and thawing so no preparation 
was refrozen after use. 
Cells.  Heparinized blood, usually diluted 1:1 with Hank's balanced salt solution, was layered 
over Ficoll-Hypaque (13), and centrifuged at 1,000g for 30 min in the Sorvall RC-3. (Ivan Sorvall, 
Inc.) The lymphocytes at the serum Ficoll interface were removed and washed three times with a 
wash solution  (medium containing only 5%  fetal calf serum).  Adult blood was obtained from 
donors working in this Institute whose age range was from 20  to 35  yr.  Fetal  cord blood was 
obtained by courtesy of Boston Lying In Hospital (Boston, Mass.). 
Cell Culture.  B and Ig-negative cells were cultured at appropriate concentrations (usually 1 × 
108/ml unless otherwise stated) in a  Linbro Mk II  microtiter plate (Linbro Chemical Co., New 
Haven, Conn.) at a final vol of 0.2 ml of medium containing 20% fetal calf serum. Infection with 
virus was usually with a 1:10 or 1:20 final dilution of viral supernate. We have observed during the 
course of these experiments that a viral dilution of 1:10 or higher allows the suppression effect to 
be reproducibly observed. When necessary, cells were fed 5-6 days after infection and, thereafter, 
every 3-4 days by replacing 0.1 ml of culture medium with fresh medium containing 20% fetal calf 
serum. 
DNA Synthesis Assay.  This method was used to assay the transformation potency of B95-8 
virus and is based on the original assay of Robinson and Miller (14). Triplicate cultures of cells (1 
× 108 ml, 2 x  105/well) were pulsed for 4 h with [3H]thymidine (50 ~1 of 2 t~Ci/ml, sp act 2 Ci/mmol) 
and harvested onto glass fiber filters. 
Radioactivity was assayed by liquid scintillation counting by using a toluene/Liquifluor scintil- 
lation  fluid  (New  England  Nuclear,  Boston,  Mass.).  All  values  for  specific  [3H]thymidine  in- 
corporation were calculated subtracting counts per minute (cpm)  in mock infected culture from 
cpm in virus infected control. 
Outgrowth Assay.  Outgrowth of transformed lymphocytes was assayed visually at the time of 
appearance of transformed cells in the culture and assessed on a  scale of one to four (Fig. 1).  A 
score of one represents only dead cells, judged by phase contrast microscopy; two, living but not 
necessarily transformed cells and clumps; three, transformed cell clumps and large transformed 
single cells in the well  (a score of two can sometimes represent a  poor three which would be 
confirmed within 2 or 3 days); four, the well overrun by transformed and proliferating cells. Each 
experiment was performed in sextuplicate and the time of  transformation in days was set as either 
the time when six wells obtain a score of three or alternatively four wells obtain a  score of four. 
The plates were read microscopically every 2 days. 
Preparation  of Rabbit Anti-Human Fab ' Immunoabsorbent Column.  The technique used was 
that described by Chess and Schlossman (15) except that 80 mg of anti-human Fab' antibody was 
coupled lightly to 300 ml of Sephadex G-200 by allowing to stand at 4°C overnight with occassional 
stirring. Coupling efficiency was usually >70%, twice that obtained by the previously described 
procedure. 
Separation  of B  and  Ig-Negative  Lymphocyte  Populations.  B  and  Ig-negative lymphocyte 
populations were prepared by passing whole lymphocyte populations over a  rabbit anti-human 
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greater than 90%.  The B-cell population was 92% pure by the criterion of surface p23,  30  (16) 
antigens (a marker for B cells and a  subpopulation of null cells) and 95% Ig positive. Both surface 
markers were assayed by the direct membrane immunofluorescence technique. The Ig-negative 
population contained 1% surface Ig-positive cells and approximately 2% p23, 30 positive cells due 
to the p23, 30 positive null cell population. 
Preparation of Ig-Negative Lymphocyte Subpopulations.  Adherent lymphocytes were removed 
by passage over nylon wool columns. T 3 and null lymphocytes were separated by means of the E- 
rosette technique. The methodology for these techniques has been described in detail elsewhere 
(15).  Macrophages were  removed from whole  peripheral  lymphocyte populations  by treatment 
with iron carbonyl and magnetism (17). 
Materials.  Tissue culture  medium and fetal calf serum were obtained from Microbiological 
Associates,  Bethesda,  Md.;  [3H]thymidine from Schwarz/Mann Div.,  Becton,  Dickinson &  Co., 
Orangeburg, N. J.; cyanogen bromide from Eastman Kodak Co., Rochester, N. Y.; human gamma 
globulin from Sigma Chemical Co., St. Louis, Mo. All other chemicals were obtained from Fisher 
Scientific Co.,  Fair Lawn, N. J.  and were all of high purity grade. 
Results 
DNA Synthesis in Separated  B Cells from Various Donors.  B cells purified 
by  chromatography on  a  rabbit  anti-human Fab'  immunoabsorbent column 
provide sensitive targets for EBV-specific stimulation of DNA synthesis (D. A. 
Thorley-Lawson and J. L. Strominger, manuscript in preparation). No stimula- 
tion of DNA synthesis is observed with the Ig-negative lymphocytes from the 
column. 
B cells from fetal cord lymphocytes and from the peripheral blood lymphocytes 
of EBV seropositive and seronegative adult donors were infected with EBV and 
the  rate  of DNA  synthesis assayed at regular intervals up  to  10  days after 
infection (Fig. 2).  The rates of proliferation as measured by the slope and the 
absolute levels of [3H]thymidine incorporation at any time were similar for all 
three donors. This suggests that there was no significant difference in either the 
number of cells infected or the rate at which the infected cells proliferated. 
Efficiency  with which EBV Causes Outgrowth  of Transformed Lymphocytes 
from Populations  of Adult and Fetal Lymphocytes.  Outgrowth experiments 
were  performed  on  fetal  and  adult  lymphocytes to  determine  whether  the 
similarity in the rates and levels of DNA synthesis after infection correlated 
with the rate of appearance of transformed cells. It is known that lymphocytes 
from fetal  cord  blood  transform  more  efficiently than those  from the  adult 
periphery (12) and this was confirmed by studies on several individuals (Table 
1). The average time for outgrowth of  adult peripheral blood lymphocytes was 25 
days, compared to only 13 days for fetal cord lymphocytes. A more detailed study 
on two individuals (Fig. 3) indicated that by using unseparated adult lympho- 
cytes only 8  of 33  infected wells  grew  out  after 6  wk,  while  24  of 24  wells 
containing fetal lymphocytes grew out after 2 wk. 
Outgrowth studies were also carried out on separated Ig-negative and B cells. 
Adult B lymphocytes grew out as fast (13-14 days) and with the same efficiency 
(100% in 2 wk) as B cells from fetal cord blood (Table I, Fig. 3). In neither case 
did EBV have any effect on the Ig-negative cell population. 
Transformation  of Reconstituted  Mixtures  of T  and B  Lymphocytes  from 
3 T, thymus-derived lymphocyte, operationally defined as E-rosette positive, surface Ig nega- 
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FIG.  2.  Time-course of DNA synthesis in B Cells from different donors induced by infec- 
tion with EBV. B lymphocytes from adult or fetal cord donors (2.105 cells in 0.2 ml) prepared 
by passage over a rabbit anti-human Fab' column were infected with EBV (final dilution 
1/10), or mock infected. Experiments were set up in triplicate and the cells pulsed at various 
times with [3H]thymidine to assess the level of DNA synthesis. The level of specific [3H] 
thymidine incorporation was estimated by subtracting the background counts obtained with 
the mock-infected cultures  from the counts in  the experimental cultures.  Background counts 
were: 30-100 cpm EBV seropositive donor, 50-10t) cpm EBV seronegative donor, 60-500 fetal 
cord lymphocytes. 
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TABLE  I 
Time to Transformation by EBV of Unseparated and Isolated Fetal Cord and Adult 
B Lymphocytes 
No. indi-  Time of  trans- 
viduals  Cell origin  Cell  type  formation 
tested  (Days) 
4  Fetal cord  Whole  13  _+  2 
4  Fetal cord  B  14  ±  2 
10  Adult PBL*  Whole  25* 
6  Adult PBL  B  13  _+  2 
* PBL, peripheral blood lymphocyte. 
Does  not  include  four  samples  which had  not  grown  out  at  time 
experiment stopped, usually 35 days. 
Adult  Peripheral  Blood  and  Fetal  Cord  Blood.  The  experiments  reported 
above  strongly  suggested  that  the  susceptibility  of human  B  lymphocytes to 
transformation  does  not  depend  on  their  fetal  or  adult  origin.  The  question 
arises, therefore,  as to the discrepancy in the efficiency with which unfraction- 
ated lymphocytes from the two sources transform (Table I, Fig. 3). One possible 
explanation  for  this  result  could  be  that  there  is  a  higher  proportion  of B 500  SUPPRESSION  OF  IN  VITRO  EPSTEIN-BARR  VIRUS  INFECTION 
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TABLE  II 
Time to Transformation by EB  V of  Reconstituted Mixtures of  Either Fetal Cord or 
Adult Lymphocytes 
Days to trans- 
Cell origin  Cell mixture (B:T)  formation 
Fetal cord  100:0,  13 
50:50  13 
20:80  13 
Unfractionated  13 
Adult PBL  100:0  13 
50:50  18 
20:80  >21 
Unfractionated  >21 
Total cells =  2.105. 
lymphocytes in fetal cord than in adult peripheral blood (18, 19). To test if this 
difference was the reason for the discrepancy, cells of both origins were sepa- 
rated, and then reconstituted into mixtures of 100, 50, and 20% B cells. 
Fetal B lymphocytes  transformed as efficiently  whether containing 100 or 20% 
B cells: 80% autologous Ig-negative cells, or whether unseparated lymphocytes 
were  used  (Table  II).  By comparison adult B  lymphocytes were  strongly in- 
hibited by the presence of 80%  autologous Ig-negative lymphocytes (the ratio 
which is found in vivo) and were slightly inhibited by 50% Ig-negative lympho- 
cytes (the ratio found in vivo with fetal cord blood). 
Two explanations for this result may be suggested. Firstly, the number of B 
lymphocytes in a  20:80 B:Ig-negative cell mixture was less than in the 50:50 
mixture, as the total cell number is constant. If adult B lymphocytes were more 
sensitive to dilution than cord B  lymphocytes, a  difference would have been D.  A.  THORLEY-LAWSON~  L.  CHESS~  AND  J.  L.  STROMINGER 
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FIG.  4.  Delay in outgrowth of adult B lymphocytes by addition of various proportions of Ig- 
negative lymphocytes aider EBV infection. Mixtures were reconstituted keeping either the 
total cell number per well constant (2.10  5 cells in 0.2 ml) O--O or keeping the number of B 
cells per well constant (1.10  ~ cells) and varying only the number of Ig-negative lymphocytes 
O--O.  Delay in outgrowth indicates number of days for infected B cells to grow out in the 
presence of Ig-negative lymphocytes minus the number of days for the same number of B 
cells to grow out alone. Viral dilution was 1:5. 
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observed in efficiency at the lower dilution. Secondly, the result could have been 
due to a suppression of the B-lymphocyte proliferation by the adult Ig-negative 
lymphocytes. 
Reconstruction  of Adult  Peripheral  Lymphocytes  to  Various  Proportions 
Keeping Either Total Cell Number or B-Cell Number Constant.  An experi- 
ment was performed with various mixtures of adult B and Ig-negative lympho- 
cytes keeping either the total cell number constant or keeping the number of B 
lymphocytes constant and varying the number of Ig-negative lymphocytes (Fig. 
4). Suppression of proliferation was measured as the days delay to outgrowth of 
infected cultures compared to controls with the same number of B cells but no 
added Ig-negative cells. Reconstitution of  the lymphocytes to the in vivo ratio of 
20:80, B:Ig-negative cells resulted in a marked suppression of the B-cell prolifer- 
ation. This effect could not be explained by dilution sensitivity because: (a) the 
effect was compared to a control with the same number of B cells; (b) the effect 
was observed at both high and low total B-cell number.  The observation that 
suppression occurred  at the same ratio  (>60%  Ig-negative cells)  in both the 502  SUPPRESSION  OF  IN  VITRO  EPSTEIN-BARR  VIRUS  INFECTION 
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FIG. 5.  Delay in outgrowth of adult B lymphocytes by addition of various subpopulations 
of Ig-negative lymphocytes after EBV infection. For experimental details see legend to Fig. 
6. Viral dilution  used was 1:20. O, ratios of B and Ig-negative lymphocytes varied keeping 
total cell number per well constant.  O, ratios of B and Ig-negative lymphocytes  varied 
keeping number of B cells per well constant. X, these points represent cultures which still 
had not grown out when the experiment was terminated. 
constant cell and constant B-cell experiments argues strongly that the suppres- 
sion of outgrowth was not due simply to cell crowding but was the  result of a 
specific interaction of adult Ig-negative lymphocytes with the infected B  cells. 
Identification  of the Ig-Negative Population Responsible for In Vitro Suppres- 
sion of EBV-Injected  Adult B Lymphocytes.  Ig-negative lymphocytes are pre- 
dominantly T cells, however, they also contain small numbers of null cells and 
macrophages. A series of experiments were, therefore, carried out to investigate 
the  role  of  these  various  populations  in  the  in  vitro  suppression  (Fig.  5). 
Removal of adherent cells by passage over a nylon wool column had no effect on 
the ability of Ig-negative lymphocytes to delay the outgrowth of infected B cells 
(50% Ig-negative lymphocytes delaying outgrowth by about 2 wk).  T  cells and 
null cells were prepared by taking E-rosette-positive and negative populations, 
respectively. The T cells were slightly more effective than the whole Ig-negative 
cells  giving  a  2-wk  delay  in  outgrowth  at  a  proportion  of about  35-40%.  By 
comparison  only the  highest  proportion  (80%)  of null  cells gave a  significant 
suppression of the outgrowth and this may be readily explained by contamina- D.  A.  THORLEY-LAWSON,  L.  CHESS,  AND  J.  L.  STROMINGER  503 
tion of the null cells by a residue of T cells. These experiments showed that the 
T-cell  population  of Ig-negative  lymphocytes  is  the  one  responsible  for  the 
suppression  effect.  The  observation  that  50%  purified  T  cells  provided  very 
effective suppression whereas 50% null cells provided none is further evidence 
that the suppression is not the result of a cell culture artifact such as overcrowd- 
ing. 
As the B-cell population used in these studies contains a significant number of 
macrophages  it  was  possible  that  they  might  play  an  indirect  role  in  the 
suppression  by  interacting  with  T  cells.  Prior  removal  of macrophages  by 
treatment  with  iron  carbonyl and  magnetism,  however,  had  no effect on the 
ability of the T cells to suppress outgrowth (Fig.  6). 
In agreement with other authors  (20,  21) we have observed that depletion of 
macrophages somewhat retards the time at which proliferation and outgrowth 
of infected B  cells occurs.  However, the effect was not large  (12-13 days com- 
pared  to  8-10  days  in  the  presence  of macrophages)  and  there  was  not  an 
absolute requirement for macrophages to obtain outgrowth. 
Discussion 
The results presented here indicate that T  lymphocytes from adults but not 
fetal cord can suppress the outgrowth of in vitro EBV-infected B lymphocytes. 
Earlier work (22-24) and results presented here indicate that EBV infects only B 
cells.  In  the  present  study no  significant  difference was observed in the  effi- 
ciency with which purified fetal or adult B  lymphocytes were transformed by 
EBV as measured by either induction of DNA synthesis or time to outgrowth of 
proliferating  cells.  Addition  of increasing  numbers  of autologous  adult  Ig- 
negative  lymphocytes, however, resulted in the time to outgrowth of adult B 
cells becoming increasingly  longer.  This did not occur when fetal Ig-negative 
lymphocytes were added  back  to  fetal  B  cells.  Trivial  explanations  that  this 
effect was due to culture artifacts such as cell crowding have been ruled out. The 
lymphocytes which were effective in this in vitro suppression of infection had the 
characteristics of being nonadherent to nylon wool and E-rosette positive indi- 
cating  that  they were T  cells.  It  appears,  therefore,  that  there  is  a  function 
associated with human T  lymphocytes which develops during  maturation  and 
allows them  to  limit  EBV  infection  of B  cells.  This  observation  provides  an 
explanation  for the  generally  accepted view  (12)  that  fetal  cord lymphocytes 
transform more efficiently in vitro than those from adult peripheral  blood. 
The mechanism of in vitro suppression of proliferation may be explained by 
several known  immune  functions  of lymphocytes.  The  most attractive  comes 
from studies in mice where it has been shown that subpopulations of T lympho- 
cytes are able to suppress the immune response of both B and T cells (25). Thus, 
murine  B-cell proliferation  and antibody production may be abrogated by the 
presence of a subpopulation of suppressor lymphocytes bearing the Ly 23 surface 
antigens  (26). 
It  appears,  therefore,  that  a  mechanism  for specifically suppressing  B-cell 
proliferation  already  exists.  Such a  mechanism  could play a  role in recovery 
from EBV infection as it is known that  individuals who have recovered from 
infectious mononucleosis carry EBV-infected cells which are suppressed in vivo 504  SUPPRESSION  OF  IN  VITRO  EPSTEINoBARR  VIRUS  INFECTION 
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FIG.  6.  Delay of outgrowth of adult B lymphocytes by T cells before and after depletion of 
macrophages.  For experimental detail see legend to Fig. 4.  @, iron carbonyl-depleted cell 
populations. O, undepeleted populations. X, these points represent cultures which had still 
not grown out when the experiment was terminated. 
in the absence of  cytotoxic lymphocytes. These cells will proliferate in culture to 
give  rise  to  EBV-positive  lymphoblastoid cell  lines  without the  addition  of 
exogenous virus (11). There must, therefore, be some mechanism by which these 
cells are kept under control in the healthy individual. There are two levels at 
which the control of the viral information could be exerted. First, it has been 
proposed that the virus is latent within the cell and only becomes activated on 
transfer to tissue culture (27). This would be a control working within the cell D.  A.  THORLEY-LAWSON,  L.  CHESS,  AND  J.  L.  STROMINGER  505 
itself. It has been demonstrated, however, that the large lymphoblasts from IM 
patients are Epstein-Barr virus nuclear antigen positive and this has been cited 
as evidence against the presence of a  latent  virus  (28).  The second method of 
control would be at the cellular level by means of suppressor cells and or release 
of soluble factors by T cells which prevent the B cells from proliferating further. 
Thus,  EBV-carrying  lymphocytes which  persist  at  a  low level  after  recovery 
from IM could be considered as EBV memory B cells. 
An alternative  explanation  for the mechanism  of suppression  would be the 
induction of cyt~toxic T cells sensitized by new antigens (29) on the surface of  the 
transformed B cells. These cytotoxic lymphocytes would stop proliferation after 
infection by actually destroying the transformed cells. This mechanism is less 
likely because human  fetal cord lymphocytes are themselves competent in T- 
cell-mediated cytotoxicity against blast transformed lymphocytes (D. A. Thor- 
ley-Lawson, unpublished observations) and yet are unable to suppress in vitro 
infection.  Furthermore,  it  could not explain  the  in vivo situation  as healthy 
adults do not carry sensitized T-killer cells after recovery from IM although the 
infected B cells persist in a  suppressed state. 
The  ineffectiveness  of purified  null  cells  in  the  suppression  of infection 
excludes  any mechanism  involving null  cells  such  as  the  natural  killer  cell 
described  in  murine  systems  and  recently  a  human  system  (30,  31)  or  the 
complement receptor-positive nonspecific killer  cell described for human  sys- 
tems (10).  A direct role of macrophages,  for example, in macrophage-mediated 
cytotoxicity (32) has similarly been excluded although for technical reasons an 
indirect role of a small number of macrophages cannot be rigorously excluded. 
The failure of fetal lymphocytes to suppress the in vitro infection suggests a 
wider potential significance for this phenomenon as both IM and African BL are 
diseases  of childhood  and  adolescence  (33,  34).  Furthermore,  failure  of T-cell 
functions  have  been  postulated  as  the  cause  of fatal  X-linked  EBV  induced 
lymphoproliferation  (Duncan's  disease)  (35).  It is conceivable, therefore,  that 
susceptibility to EBV-associated disease is also associated with a  failure of the 
mechanisms involved in the in vitro suppression of EBV infection. It will be of 
critical  importance  in  understanding  this  relationship  to  test  the  ability  of 
genetically susceptible and immunosuppressed individuals to suppress in vitro 
EBV infection. 
The results also lead to two important technical advances which are of general 
importance and, therefore, worthy of comment. First, the inefficient and unreli- 
able transformation  of whole  adult  lymphocytes makes  the  establishment  of 
permanent cell lines difficult. However, when using separated B lymphocytes, it 
has,  in our hands,  been possible to obtain growing cell lines in less than 2 wk 
with 100% efficiency from all adult lymphocytes. Furthermore, the growing cells 
have not been subject to selection in the presence of, for example, potentially 
cytotoxic T cells. Second, purified adult B cells provide a more effective, reliable, 
and  reproducible  source  of targets  for  transformation  assays  than  the  more 
commonly used fetal cord lymphocytes. 
Summary 
Studies  have  been  performed  on  in  vitro  infection  by  Epstein-Barr  virus 506  SUPPRESSION  OF  IN  VITRO  EPSTEIN-BARR  VIRUS  INFECTION 
(EBV) of subpopulations  of human  lymphocytes. B  cells of adult peripheral or 
fetal  cord  blood  transform  with  equal  efficiency,  whether  assayed  by  DNA 
synthesis  induction  or by outgrowth  of transformed lymphocytes. In contrast, 
unfractionated  adult  lymphocytes transform  much  less  efficiently than  those 
from fetal cord.  Reconstitution  experiments of different cell preparations indi- 
cated  that  this  difference  was  due to  a  suppression  of B-cell  proliferation  by 
adult Ig-negative lymphocytes which fetal Ig-negative lymphocytes were unable 
to perform.  Separation of Ig-negative lymphocytes into various subpopulations 
revealed that the suppression was performed by T  cells. Macrophages and null 
cells play little or no role in suppression.  The relevance of this phenomenon to 
infection and recovery from EBV infection during and after infectious mononu- 
cleosis is discussed. 
Received for publication 31  March 1977. 
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